SUBSCRIBE
SUBSCRIBE
News   Drug Development

First Patient Treated in BioInvent’s Phase I Study of the Drug Candidate BI-505 to Treat Multiple Myeloma

January 4, 2010 | 
1 min read
Bookmark and Share

LUND, Sweden--(BUSINESS WIRE)--BioInvent International AB (STO:BINV) announced today that the first patient has been treated in an open, dose-escalation phase I study of the company’s antibody BI-505 for patients with advanced multiple myeloma.
Clinical research Phase I Europe
MORE ON THIS TOPIC
Profile view, and Mental Illness
Depression
Alto Digs Into Exploratory Outcomes as Depression Drug Misses Phase II Endpoint
June 27, 2025
 · 
2 min read
 · 
Tristan Manalac
Artwork magazine collage picture of serious confident lady looking big enlargement glass isolated drawing background.
Immunology and inflammation
Nektar Declares Phase IIb Eczema Win for Rezpeg—But Analysts Unconvinced
June 25, 2025
 · 
3 min read
 · 
Tristan Manalac
Illustration showing scientist climbing up DNA spiral staircase
Gene therapy
Sangamo’s ‘Positive’ Phase I/II Data for Fabry Gene Therapy Opens Path to FDA
June 24, 2025
 · 
3 min read
 · 
Tristan Manalac
People And Robots Handshake Modern Human And Artificial Intelligence Futuristic Mechanism Technology Vector Illustration
Artificial intelligence
In latest AI Play, Sanofi Bets $630M+ for Formation Bio’s JAK/SYK Blocker
June 24, 2025
 · 
2 min read
 · 
Tristan Manalac